Corient Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $309K | Hold |
2,121
| – | – | 0.02% | 450 |
|
|
2022
Q2 | $309K | Sell |
2,121
-155
| -7% | -$22.6K | 0.02% | 464 |
|
|
2022
Q1 | $372K | Sell |
2,276
-36
| -2% | -$5.88K | 0.02% | 461 |
|
|
2021
Q4 | $392K | Buy |
2,312
+38
| +2% | +$6.44K | 0.03% | 432 |
|
|
2021
Q3 | $429K | Buy |
2,274
+246
| +12% | +$46.4K | 0.03% | 400 |
|
|
2021
Q2 | $344K | Buy |
2,028
+198
| +11% | +$33.6K | 0.03% | 455 |
|
|
2021
Q1 | $258K | Buy |
1,830
+219
| +14% | +$30.9K | 0.02% | 491 |
|
|
2020
Q4 | $209K | Buy |
+1,611
| New | +$209K | 0.02% | 468 |
|
|
2020
Q3 | – | Sell |
-1,460
| Closed | -$216K | – | 509 |
|
|
2020
Q2 | $216K | Buy |
+1,460
| New | +$216K | 0.03% | 416 |
|